Molecular and mechanistic characterization of platelet-activating factor-like bioactivity produced upon LDL oxidation

被引:19
作者
Androulakis, N
Durand, H
Ninio, E
Tsoukatos, DC [1 ]
机构
[1] Univ Ioannina, Dept Chem, GR-45110 Ioannina, Greece
[2] Univ Paris 06, Fac Med Pitie Salpetriere, Inst Nacl Sante & Rech Med, U525, F-75643 Paris, France
关键词
oxidized phospholipids; platelet-activating factor-acetylhydrolase; platelet-activating factor-transacetylase; mediators of inflammation; atherogenesis; low density lipoprotein;
D O I
10.1194/jlr.M500074-JLR200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oxidation of LDL is thought to be involved in both initiating and sustaining atherogenesis through the formation of proinflammatory lipids and the covalent modification of LDL particles. Platelet- activating factor (PAF; 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a potent phospholipid mediator involved in inflammation. Upon oxidation of LDL, oxidized phospholipids with PAF-like structure are generated, and some of them may act via the PAF receptor. We evaluated the contribution of 1-0-hexadecyl-2-acetylsn-glycero-3-phosphocholine (C16:0 PAF) and of other PAF analogs on the PAF-like bioactivity formed upon Cu2+- initiated oxidation of LDL. Reverse-phase HPLC purification and electrospray ionization-MS analyses showed that upon oxidation of LDL with inactivated PAF-acetylhydrolase (PAF-AH), C16:0 PAF accounted for > 30% of PAF-like biological activity and its sn-2 butenoyl analog accounted for > 50%. However, upon LDL oxidation in the presence of exogenous 1-0-alkyl-sn-glycero-3-phosphocholine (lyso-PAF) without PAF-AH inactivation, C16:0 PAF formation accounted for > 90% of the biological activity recovered. We suggest that the C16:0 PAF, despite being a minor constituent of the LDL peroxidation products, may contribute substantially to the bioactivity formed in oxidized LDL. The higher bioactivity of C16:0 PAF, and the higher selectivity of the LDL-attached lyso-PAF transacetylase toward very short acyl chains [acetate (C2) vs. butanate (C4)], may explain the contribution described above.
引用
收藏
页码:1923 / 1932
页数:10
相关论文
共 46 条
[1]   BICYCLIC ENDOPEROXIDES AND SYNTHETIC APPLICATIONS [J].
BALCI, M .
CHEMICAL REVIEWS, 1981, 81 (01) :91-108
[2]  
BARLETT GR, 1959, J BIOL CHEM, V234, P466
[3]   STRUCTURAL-ANALYSIS OF PURIFIED PLATELET-ACTIVATING FACTOR BY LIPASES [J].
BENVENISTE, J ;
LECOUEDIC, JP ;
POLONSKY, J ;
TENCE, M .
NATURE, 1977, 269 (5624) :170-171
[4]   ATHEROSCLEROSIS - BASIC MECHANISMS - OXIDATION, INFLAMMATION, AND GENETICS [J].
BERLINER, JA ;
NAVAB, M ;
FOGELMAN, AM ;
FRANK, JS ;
DEMER, LL ;
EDWARDS, PA ;
WATSON, AD ;
LUSIS, AJ .
CIRCULATION, 1995, 91 (09) :2488-2496
[5]  
BLANKSBY B, 1981, AUST J SPORT SCI, V1, P3
[6]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[7]  
BOSSANT MJ, 1990, METHOD ENZYMOL, V187, P125
[8]  
Camejo German, 1993, Current Opinion in Lipidology, V4, P385, DOI 10.1097/00041433-199310000-00007
[9]   BIOSYNTHESIS OF PLATELET-ACTIVATING-FACTOR AND 1-O-ACYL ANALOGS BY ENDOTHELIAL-CELLS [J].
CLAY, KL ;
JOHNSON, C ;
WORTHEN, GS .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1094 (01) :43-50
[10]   PAF-ACETHER-DEGRADING ACETYLHYDROLASE IN PLASMA LDL IS INACTIVATED BY COPPER-MEDIATED AND CELL-MEDIATED OXIDATION [J].
DENTAN, C ;
LESNIK, P ;
CHAPMAN, MJ ;
NINIO, E .
ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (03) :353-360